Virtual medical education event on

PARP inhibitors in prostate cancer:

Practical considerations for clinical practice

Dr. Joaquin Mateo

Group Leader, Prostate Cancer Translational Research Group
Institute of Oncology Vall d’Hebron University Hospital,
Barcelona, Spain

Dr. Avivit Peer

Head of clinical trial unit, Head of Genitourinary clinic, Oncology institute
Rambam Health care Campus. Haifa, Israel

Prof. Dov Hershkovitz

Director - Institute of Pathology
Tel-Aviv Medical Sourasky Center, Israel

Dr. Meital Levartovsky

Senior oncologist, GU unit, Department of oncology
Sheba Medical Center, Israel

Date Tuesday, 30 November 2021

Time 19:00-20:30

desktop Live “Open Mic” webcast through “TEAMS” platform


  • 19:00 – 19:05 Welcome and introduction
  •   Moderator - Dr. Avivit Peer
  • Optimizing outcomes for mCRPC patients
  • 19:05 – 19:30 The emerging role of PARP inhibitors in prostate cancer
  •   Dr. Joaquin Mateo
  • BRCA 1, BRCA 2 and ATM -Testing Journey
  • 19:30 – 19:45 The pathologist perception on real life implementation of molecular testing and tissue sampling in prostate cancer
  •   Prof. Dov Hershkovitz
  • From international guidelines into clinical practice - The oncologist perspective
  • 19:45 - 20:05 Management of patients with mCRPC harbouring BRCA alterations – case studies presentation
  •   Dr. Meital Levartovsky
  • 20:05 – 20:30 Therapeutic implications of PARPi treatment in the mCRPC clinical landscape
  •   All